NCT06325683 2026-04-15
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
8 trialsNCT03952598 2026-04-14
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT03375307 2026-04-13
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
National Cancer Institute (NCI)
Phase 2 Suspended
NCT04616560 2026-04-13
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05223036 2026-04-13
Testing Obeticholic Acid for Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05554380 2026-04-13
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05960773 2026-03-27
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT00003067 2009-02-09
Biological Therapy in Treating Patients With Primary or Advanced Glioma
National Cancer Institute (NCI)
Phase 2 Suspended